Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65,880 | 24 | 49.9% |
| Consulting Fee | $37,560 | 10 | 28.4% |
| Travel and Lodging | $14,062 | 51 | 10.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,200 | 2 | 3.9% |
| Food and Beverage | $4,963 | 88 | 3.8% |
| Honoraria | $4,450 | 2 | 3.4% |
| Education | $7.93 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $46,514 | 63 | $0 (2022) |
| AbbVie Inc. | $41,000 | 69 | $0 (2020) |
| Alexion Pharmaceuticals, Inc. | $17,218 | 11 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $10,392 | 10 | $0 (2018) |
| Intercept Pharmaceuticals, Inc. | $6,808 | 6 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $6,764 | 8 | $0 (2017) |
| ORPHALAN INC | $3,185 | 3 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $129.15 | 1 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.21 | 2 | $0 (2022) |
| Janssen Biotech, Inc. | $28.05 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $142.30 | 2 | Ipsen Biopharmaceuticals, Inc ($129.15) |
| 2023 | $6,072 | 3 | ORPHALAN INC ($3,172) |
| 2022 | $12,136 | 12 | Alexion Pharmaceuticals, Inc. ($11,998) |
| 2021 | $2,320 | 1 | Alexion Pharmaceuticals, Inc. ($2,320) |
| 2020 | $1,839 | 4 | AbbVie Inc. ($1,800) |
| 2019 | $5,529 | 17 | AbbVie, Inc. ($5,515) |
| 2018 | $11,624 | 23 | AbbVie, Inc. ($6,001) |
| 2017 | $92,461 | 116 | Gilead Sciences Inc ($46,160) |
All Payment Transactions
178 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/08/2024 | ORPHALAN INC | CUVRIOR (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: Hepatology | ||||||
| 08/14/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $129.15 | General |
| Category: Rare Disease | ||||||
| 11/13/2023 | ORPHALAN INC | CUVRIOR (Drug) | Food and Beverage | In-kind items and services | $172.10 | General |
| Category: Hepatology | ||||||
| 11/10/2023 | ORPHALAN INC | CUVRIOR (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Hepatology | ||||||
| 04/13/2023 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| 11/05/2022 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $54.56 | General |
| 11/04/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $107.60 | General |
| 09/08/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: Immunology | ||||||
| 08/18/2022 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $235.17 | General |
| 08/18/2022 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.64 | General |
| 08/16/2022 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,440.00 | General |
| 07/21/2022 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $394.19 | General |
| 07/21/2022 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $302.90 | General |
| 07/21/2022 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $274.83 | General |
| 07/21/2022 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $151.76 | General |
| 07/21/2022 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $124.50 | General |
| 06/14/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: Gastroenterology | ||||||
| 11/30/2021 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,320.00 | General |
| 08/03/2020 | Gilead Sciences, Inc. | Vemlidy (Drug) | Education | In-kind items and services | $7.93 | General |
| Category: HBV | ||||||
| 07/22/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/21/2020 | AbbVie Inc. | MAVYRET (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: VIROLOGY | ||||||
| 01/17/2020 | Janssen Biotech, Inc. | STELARA (Biological), STELARA | Food and Beverage | In-kind items and services | $12.12 | General |
| Category: Immunology | ||||||
| 11/10/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $41.87 | General |
| Category: Virology | ||||||
| 11/06/2019 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: HEPATOLOGY GASTROENTEROLOGY | ||||||
| 06/05/2019 | AbbVie, Inc. | Mavyret (Drug) | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| Category: Virology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 330 | 425 | $137,355 | $47,309 |
| 2022 | 9 | 380 | 519 | $131,702 | $56,370 |
| 2021 | 6 | 274 | 367 | $115,638 | $45,205 |
| 2020 | 10 | 322 | 430 | $130,662 | $43,054 |
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 82 | 106 | $42,972 | $15,253 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 94 | $28,760 | $9,841 | 34.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $13,443 | $4,323 | 32.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 36 | 38 | $9,928 | $4,322 | 43.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 26 | 65 | $13,386 | $4,204 | 31.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 26 | $7,435 | $2,564 | 34.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $6,692 | $1,963 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 23 | 23 | $3,716 | $1,779 | 47.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $6,368 | $1,731 | 27.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 20 | $4,655 | $1,331 | 28.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 76 | 96 | $34,000 | $14,518 | 42.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 83 | 99 | $27,165 | $10,545 | 38.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 44 | 113 | $21,018 | $9,640 | 45.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 25 | 25 | $12,225 | $4,581 | 37.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 24 | $7,800 | $3,965 | 50.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 25 | 29 | $6,380 | $3,540 | 55.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 28 | 31 | $4,340 | $2,552 | 58.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 20 | 43 | $6,063 | $2,530 | 41.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $5,570 | $1,810 | 32.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 15 | $3,410 | $994.91 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 17 | $1,716 | $911.46 | 53.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 13 | 13 | $2,015 | $781.90 | 38.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 83 | 117 | $40,655 | $16,522 | 40.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 37 | 37 | $17,835 | $6,968 | 39.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 49 | 51 | $11,220 | $6,180 | 55.1% |
About Dr. Kenneth Rothstein, MD
Dr. Kenneth Rothstein, MD is a Transplant Hepatology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790753317.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Rothstein, MD has received a total of $132,123 in payments from pharmaceutical and medical device companies, with $142.30 received in 2024. These payments were reported across 178 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($65,880).
As a Medicare-enrolled provider, Rothstein has provided services to 1,306 Medicare beneficiaries, totaling 1,741 services with total Medicare billing of $191,938. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Practice Information
- Specialty Transplant Hepatology
- Other Specialties Gastroenterology, Internal Medicine
- Location Philadelphia, PA
- Active Since 03/09/2006
- Last Updated 10/04/2019
- Taxonomy Code 207RT0003X
- Entity Type Individual
- NPI Number 1790753317
Products in Payments
- Mavyret (Drug) $30,750
- Epclusa (Drug) $24,021
- Viekira (Drug) $8,450
- Vemlidy (Drug) $6,847
- OCA (Drug) $6,794
- ZEPATIER (Drug) $6,764
- Nexavar (Drug) $5,365
- Stivarga (Drug) $5,027
- Harvoni (Drug) $5,000
- Vosevi (Drug) $4,664
- CUVRIOR (Drug) $3,185
- MAVYRET (Drug) $1,800
- IQIRVO (Drug) $129.15
- XIFAXAN (Drug) $34.21
- TruClear (Device) $19.70
- Amitiza (Drug) $16.88
- REMICADE (Biological) $15.93
- DARAPRIM (Drug) $14.82
- OCALIVA (Drug) $13.22
- STELARA (Biological) $12.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Transplant Hepatology Doctors in Philadelphia
Jorge Marrero, M.d, M.D
Transplant Hepatology — Payments: $20,120
Dr. Yedidya Saiman, M.d., Ph.d, M.D., PH.D
Transplant Hepatology — Payments: $7,221
Dr. David Sass, Md, MD
Transplant Hepatology — Payments: $6,133
Jill Nauss, Pa-C, PA-C
Transplant Hepatology — Payments: $563.66
Ms. Yii Chun Khiew, Md, MD
Transplant Hepatology — Payments: $123.85
Therese Bittermann, Md, MD
Transplant Hepatology — Payments: $102.75